TOCA vs. NERV, TLPH, GLTO, NRBO, AVTX, AYTU, PIRS, ORGS, RNXT, and FLGC
Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Minerva Neurosciences (NERV), Talphera (TLPH), Galecto (GLTO), NeuroBo Pharmaceuticals (NRBO), Avalo Therapeutics (AVTX), Aytu BioPharma (AYTU), Pieris Pharmaceuticals (PIRS), Orgenesis (ORGS), RenovoRx (RNXT), and Flora Growth (FLGC). These companies are all part of the "medical" sector.
Tocagen (NASDAQ:TOCA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Tocagen has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.
Minerva Neurosciences has a consensus price target of $11.00, indicating a potential upside of 334.78%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Tocagen.
Minerva Neurosciences has lower revenue, but higher earnings than Tocagen. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
21.4% of Tocagen shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 10.9% of Tocagen shares are held by insiders. Comparatively, 6.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Minerva Neurosciences received 104 more outperform votes than Tocagen when rated by MarketBeat users. However, 66.03% of users gave Tocagen an outperform vote while only 60.98% of users gave Minerva Neurosciences an outperform vote.
In the previous week, Minerva Neurosciences had 3 more articles in the media than Tocagen. MarketBeat recorded 3 mentions for Minerva Neurosciences and 0 mentions for Tocagen. Minerva Neurosciences' average media sentiment score of 0.05 beat Tocagen's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.
Minerva Neurosciences has a net margin of 0.00% compared to Tocagen's net margin of -176,433.34%. Minerva Neurosciences' return on equity of 0.00% beat Tocagen's return on equity.
Summary
Minerva Neurosciences beats Tocagen on 10 of the 15 factors compared between the two stocks.
Get Tocagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
